Pending Policies - Medicine


Measurement of Serum Antibodies to Infliximab and Adalimumab

Number:MED207.153

Effective Date:04-15-2018

Coverage:

*CAREFULLY CHECK STATE REGULATIONS AND/OR THE MEMBER CONTRACT*

Measurement of antibodies to infliximab in a patient receiving treatment with infliximab, either alone or as a combination test which includes the measurement of serum infliximab levels, is considered experimental, investigational and/or unproven.

Measurement of antibodies to adalimumab in a patient receiving treatment with adalimumab, either alone or as a combination test, which includes the measurement of serum adalimumab levels, is considered experimental, investigational and/or unproven.

NOTE: See Medical Policy RX501.051 - “Biologic Response Modifiers (BRM’s) for the Treatment of Rheumatoid Arthritis (RA) and Other Chronic Inflammatory Diseases” for coverage indications specific to infliximab and/or adalimumab.

Description:

Infliximab and Adalimumab in Autoimmune Disease

Infliximab is a chimeric (mouse/human) anti-tumor necrosis factor α (TNF-α) monoclonal antibody. Adalimumab is a fully human monoclonal antibody to TNF-α. Therapy with monoclonal antibodies has revolutionized therapy in patients with inflammatory diseases such as inflammatory bowel disease (IBD; Crohn’s disease, ulcerative colitis), rheumatoid arthritis, and psoriasis. These agents are generally given to patients who fail conventional medical therapy, and they are typically highly effective for induction and maintenance of clinical remission. However, not all patients respond, and a high proportion of patients lose response over time. An estimated one-third of patients do not respond to induction therapy (primary nonresponse), and among initial responders, response wanes over time in approximately 20% to 60% of patients (secondary nonresponse). The reasons for therapeutic failures remain a matter of debate but include accelerated drug clearance (pharmacokinetics) and neutralizing agent activity (pharmacodynamics) due to antidrug antibodies (ADA). (1) ADA are also associated with injection-site reactions (adalimumab) and acute infusion reactions and delayed hypersensitivity reactions (infliximab). As a fully human antibody, adalimumab is considered less immunogenic than chimeric antibodies, like infliximab.

Detection of ADA

The detection and quantitative measurement of ADA is difficult, owing to drug interference and identifying when antibodies likely have a neutralizing effect. First-generation assays, (i.e., enzyme-linked immunosorbent assays [ELISA]) can measure only ADA in the absence of detectable drug levels, due to interference of the drug with the assay. Other techniques available for measuring antibodies include the radioimmunoassay (RIA) method, and more recently, the homogenous mobility shift assay (HMSA) using high-performance liquid chromatography. Disadvantages of the RIA method are associated with the complexity of the test and prolonged incubation time, and safety concerns related to the handling of radioactive material. The HMSA has the advantage of being able to measure ADA when infliximab is present in the serum. Studies evaluating the validation of results among different assays are lacking, making interstudy comparisons difficult. One retrospective study (2012) in 63 patients demonstrated comparable diagnostic accuracy between 2 different ELISA methods in patients with IBD (i.e., double antigen ELISA and antihuman lambda chain-based ELISA). (2) This study did not include an objective clinical and endoscopic scoring system for validation of results.

Treatment Options for Patients with Secondary Loss of Response to Anti-TNF Therapy

A diminished or suboptimal response to infliximab or adalimumab can be managed in several ways: shortening the interval between doses, increasing the dose, switching to a different anti-TNF agent (in patients who continue to have loss of response after receiving the increased dose), or switching to a non-anti-TNF agent.

Regulatory Status

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests (LDTs) must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments. Laboratories that offer LDTs must be licensed by Clinical Laboratory Improvement Amendments for high-complexity testing. To date, the U.S. Food and Drug Administration (FDA) has chosen not to require any regulatory review of this test.

Prometheus® Laboratories (San Diego, CA), a College of American Pathologists?accredited lab under the Clinical Laboratory Improvement Amendments, offers non-radio-labeled, fluid-phase HMSA tests called Anser™ IFX (for infliximab) and Anser™ ADA (for adalimumab). Neither test is based on an ELISA test, and each can measure ADA in the presence of detectable drug levels, improving on a major limitation of the ELISA method. Both tests measure serum drug concentrations and ADA.

Rationale:

This medical policy was created in March 2014 and has been updated periodically with searches of the MEDLINE database. The most recent literature update was performed through September 11, 2017.

Validation of the clinical use of any genetic test focuses on 3 main principles: 1) analytic validity, which refers to the technical accuracy of the test in detecting a variant that is present or in excluding a variant that is absent; 2) clinical validity, which refers to the diagnostic performance of the test (sensitivity, specificity, positive and negative predictive values) in detecting clinical disease; and 3) clinical utility (i.e., how the results of the diagnostic test will be used to change management of the patient and whether these changes in management lead to clinically important improvements in health outcomes). The following is a summary of the key literature.

Antibodies to Infliximab and Adalimumab

The literature was assessed to identify studies on the analytic validity, clinical validity, and clinical utility of measuring serum antidrug antibodies (ADA). Most studies evaluating antibodies to infliximab (ATI) or to adalimumab (ATA) have reported serum drug together with ADA levels, and correlate levels to disease response. Serum drug levels and disease response are not addressed in this medical policy, which focuses instead on the data reported on ADA.

Most evidence concerning testing for ADA is derived from the data available for patients with inflammatory bowel disease (IBD) and rheumatoid arthritis (RA). Less literature exists on other diseases comprising spondyloarthropathies (SpA; e.g., ankylosing spondylitis, psoriatic arthritis, IBD-related arthritis, reactive arthritis, juvenile idiopathic arthritis) and psoriasis.

Analytic Validity

Measurement of ATI

Wang et al. (2012) developed and validated a non-radio-labeled homogeneous mobility shift assay (HMSA) to measure ATI and infliximab levels in serum samples. (2) Full method validation was performed on both the ATI- and infliximab-HMSA, and the clinical sample test results were compared with those obtained from a bridging enzyme-linked immunosorbent assay (ELISA) method to evaluate the difference in performance between the 2 assays. Intra- and interassay precision rates (as indicated by the coefficient of variation [CV]) for the ATI- and infliximab-HMSA were less than 4% and less than 15%, respectively, and less than 6% and less than 15%, respectively, considered to be robust. Hernandez-Breijo et al. (2016) (4) described the use of the HMSA protocol in measuring ATI in 50 infliximab-treated Crohn disease (CD) patients, using methods similar to Wang et al.

Sera from 100 healthy subjects (blood bank donors) were tested to determine assay cut points, defined to have an upper limit of approximately 97.5%. Using receiver operating characteristic analysis, a cut point of 1.19 μg/mL was calculated for ATI, yielding a sensitivity of 95% (95% confidence interval [CI], 89% to 98%) with a false-positive rate of 3%. For serum infliximab levels, a cut point of 0.98 μg/mL was calculated; the false-positive rate with this cut point was 5%. One hundred serum samples that previously tested positive with ELISA were reanalyzed by the new method. There was a high correlation between the 2 methods for ATI levels (p<0.001). The new method identified five false-positive samples from the bridging ELISA method, thought to be due to a higher rate of nonspecific binding in the ELISA method.

In 2014, Steenholdt et al. published a post hoc comparison of different ATI assays. (5) Blood samples were collected from 66 (96%) of 69 patients enrolled in a 2014 randomized controlled trial (RCT) that assessed algorithmic treatment for CD relapse during infliximab therapy. (6) Samples were analyzed by 3 binding assays (radioimmunoassay [RIA], ELISA, HMSA) and by a reporter gene assay (a functional cell-based technique). ATI were detected in 18 (27%) patients by RIA, in 6 (9%) patients by ELISA, and in 22 (33%) patients by HMSA. The reporter gene assay detected anti-infliximab activity, most likely due to ATI, in 7 (11%) patients. As observed by the authors, findings suggested that ATI detected by RIA and HMSA are not necessarily functionally active or neutralizing. Five (8%) patients were ATI-positive, and 43 (65%) patients were ATI-negative by all 4 assays. Correlations were statistically significant (p<0.001) for all pairwise comparisons (r range, 0.77-0.96). However, statistical agreement between assays could not be estimated accurately (e.g., using the intraclass correlation coefficient) because different assays reported values on different arbitrary scales. Regardless of assay used, most patients (range, 74%-88%) had therapeutic serum infliximab levels and undetectable ATI, suggesting nonpharmacologic reasons for relapse or for symptoms mimicking relapse.

Measurement of ATA

Wang et al. (2013) developed and validated a non-radio-labeled HMSA to measure ATA and adalimumab levels in serum samples. (7) Analytic validation of performance characteristics (i.e., calibration standards, assay limits, intra- and interassay precision, linearity of dilution, substance interference) was performed for both the ATA- and adalimumab-HMSA. Because the elimination half-life of adalimumab (10-20 days) overlaps the dosing interval (every 2 weeks), ATA-positive sera to provide calibration standards were difficult to collect (i.e., the drug-free interval for antibody formation is short). Therefore, antisera from rabbits immunized with adalimumab were pooled to form calibration standards. Serial dilutions of these ATA calibration standards then generated a standard curve against which test samples were compared. Over 29 experimental runs, intra-assay precision and accuracy for the adalimumab HMSA (as indicated by the CV) were less than 20% and 3%, respectively; interassay (run-to-run, analyst-to-analyst, instrument-to-instrument) precision and accuracy were less than 12% and less than 22%, respectively. For the ATA-HMSA, CVs for intra-assay precision and accuracy were less than 3% and 13%, respectively; CVs for interassay precision and accuracy were less than 9% and 18%, respectively. ELISA could not be used as a standard comparator due to competition from circulating drug.

Following evaluation of the analytic validity of the non-radio-labeled HMSA assay, investigators tested sera from 100 healthy subjects (obtained from blood bank donors) to determine the cut points of the assay, defined as the threshold above which samples were deemed to be positive with an upper limit of approximately 99%. The calculated cut point for serum adalimumab levels was 0.68 μg/mL, yielding a false-positive rate of 3%. For ATA, the calculated cut point was 0.55 U/mL, which yielded a false-positive rate of 1%. Analysis of 100 serum samples from patients who were losing response to adalimumab showed that 44% were above the cut point for ATA and 26% were below the cut point for serum adalimumab level. In samples below the adalimumab cut point (0.68 μg/mL), 68% were ATA-positive; in samples with adalimumab levels greater than 20 μg/mL, 18% were ATA-positive.

Section Summary: Analytic Validity

Analytic validity of ATI testing by HMSA has been demonstrated using ELISA as a standard comparator. Test performance characteristics were considered robust. However, a subsequent comparative study identified substantial variability across ATI assay methods using a functional cell-based assay as standard. The pharmacokinetic properties of adalimumab (long half-life relative to dosing interval) prevented the use of ELISA as a standard comparator in tests of ATA analytic validity. Test performance characteristics were determined by comparison with a standard curve generated by serial dilutions of pooled rabbit antisera. Lack of comparison with an alternative method of antibody detection raises uncertainty about the analytic validity of the ATA test. The commercial Prometheus HMSA assays do not suffer from many of the technical performance limitations of older assays; however, the HMSA assays do not distinguish between neutralizing and non-neutralizing antibodies. (8)

Clinical Validity

There is a substantial body of evidence (numerous systematic reviews and meta-analyses) examining associations between ADA and nonresponse as well as injection- or infusion-site reactions. Accordingly, the review of the evidence on clinical validity focuses on the most current systematic reviews (see Tables 1 through 3) and studies published after the search dates of those reviews, (9) as well as relevant studies not included in identified reviews (e.g., those focusing on adverse reactions and ADA).

Systematic Reviews

Six reviews published from 2012 through 2017 were identified. (8, 10-14) The number of studies included ranged from 11 (12) to 68 (13) varying by review objectives and conditions of interest. Although not detailed here, there was considerable overlap in selected studies across reviews.

Lee et al. (2012) conducted a meta-analysis of patients with IBD receiving infliximab to estimate the prevalence of ATI, effect of ATI on the prevalence of infusion reactions, and the effect of ATI on disease remission rates. (11) Databases were searched through October 2011, and 18 studies (total N=3326 patients) were selected. Studies included 9 RCTs, 5 prospective cohort studies, and 4 retrospective cohort studies. The prevalence of ATI was 45.8% when episodic infusions of infliximab were given and 12.4% when maintenance infliximab was given (see Table 1). Patients with ATI were less likely to be in clinical remission (see Table 2), but this finding was not statistically significant (relative risk [RR], 0.90; 95% CI, 0.79 to 1.02; p=0.10). Rates of infusion reactions were significantly higher in patients with ATI (RR=2.07; 95% CI, 1.61 to 2.67; see Table 3). Immunosuppressants resulted in a 50% reduction in the risk of developing ATI (p<0.001). Reviewers concluded that patients with IBD who test positive for ATIs are at an increased risk of infusion reactions but have rates of remission similar to patients who test negative for ATIs.

Nanda et al. (2013) conducted a meta-analysis of studies that reported on clinical outcomes according to the presence or absence of ATI in patients with IBD. (12) Several databases were searched to February 2012 (one was searched to August 2012). Eleven studies involving 707 patients were selected. Six studies (2 RCTs, 1 prospective cohort study, 3 retrospective cohort studies) were included. Selected studies failed at least 1 quality domain (study eligibility criteria, measurement of exposure and outcome, control for confounders, completeness of follow-up), and all studies had high risk of bias. The prevalence of detectable ATI in the included studies ranged from 22.4% to 46% (see Table 1). The outcome of interest was loss of response to infliximab, defined as “relapse of clinical symptoms in patients who were in clinical remission from, or had responded to, infliximab.” Measures of loss of response varied across studies and included clinician assessment, standardized scales (Crohn’s Disease Activity Index [CDAI], Harvey-Bradshaw Index, Simple Clinical Colitis Activity Index), and the requirement for surgery or presence of nonhealing fistula. Patients with ATIs had a 3-fold greater risk of loss of response than those without ATIs (RR=3.2; 95% CI, 2.0 to 5.0; shown in Table 1 as the RR of clinical response in treated vs untreated patients to allow comparison with other meta-analyses). This result was influenced primarily by 532 patients with CD (RR=3.2; 95% CI, 1.9 to 5.5); pooled results for 86 patients with ulcerative colitis were not statistically significant (pooled RR=2.2; 95% CI, 0.5 to 9.0). (Eighty-nine patients with unspecified IBD also were included in the meta-analysis.) In addition to potential bias in included studies and heterogeneity in outcome assessment, the meta-analysis was limited by variability in the method of ATI detection (double-antigen ELISA, antihuman lambda chain-based ELISA, fluid-phase RIA).

Garces et al. (2013) performed a meta-analysis of studies of infliximab and adalimumab used to treat RA, IBD, SpA, and psoriasis. (10) Databases were searched to August 2012, and reviewers selected 12 prospective cohort studies involving 860 patients (540 with RA, 132 with SpA, 130 with IBD, 58 with psoriasis). The outcome of interest was response, assessed using standard assessment scales for rheumatologic diseases (e.g., European League Against Rheumatism criteria for RA; Assessment in Ankylosing Spondylitis 20% response criteria, or Ankylosing Spondylitis Disease Activity Score for spondyloarthritis; Psoriasis Area and Severity Index for psoriasis) and clinician assessment for IBD. Overall, detectable ADA were associated with a 68% reduction in drug response (pooled RR=0.32; 95% CI, 0.22 to 0.48). Significant heterogeneity was introduced by varying use of immunosuppressant therapy (e.g., methotrexate) across studies. To assess ADA, most studies used RIA, which is less susceptible than ELISA to drug interference and may be more accurate.

A systematic review and meta-analysis by Thomas et al. (2015) included 68 studies (total N=14,651 patients). (13) Patients had RA (n=8766), SpA (n=1534), or IBD (n=4351). Immunogenicity was examined for infliximab (39 comparisons), adalimumab (15), etanercept (5), golimumab (14), and certolizumab (8). Reviewers identified studies published through December 2013 and included 38 RCTs and 30 observational studies (study quality rated as good [n=32], moderate [n=26], poor [n=10]). The pooled prevalence of ADA varied by disease and drug (see Table 1, highest with infliximab: 25.3%). Duration of exposure (reported in 60 studies) was examined for its potential effect on the development of ADA, and most studies employed ELISA assays. The presence of ADA was associated with lower odds of response across most drugs and diseases (see Table 2). An exception was in studies of IBD (similar to that reported by Lee et al.). Use of immunosuppressive agents substantially decreased the risk of ADA (odds ratio [OR], 0.26; 95% CI, 0.21 to 0.32). Finally, infusion reactions and injection-site reactions were more common (see Table 3) when ADA were detectable (OR=3.25; 95% CI, 2.35 to 4.51). Evaluation of potential publication bias and overall assessment (e.g., GRADE or similar) for the body of evidence were not reported. Additionally, no measures of heterogeneity were reported.

The systematic review by Meroni et al. (2015) searched PubMed through March 2013 and included 57 studies of infliximab (n=34), adalimumab (n=18), and etanercept (n=5). (8) Studies primarily included patients with IBD and RA, but also SpA and psoriasis. Most had prospective cohort designs (n=42), and a formal assessment of study quality (bias) was not reported. Reviewers noted considerable variability in the time from drug administration to ADA and drug bioavailability testing across studies. Various antibody testing assay methods were used and included solid-phases RIA, traditional ELISA, fluid-phase RIA, and bridging ELISA; cutoffs for positive test results were also inconsistently reported. The ranges of patients with detectable ADA varied substantially (see Table 1) but were consistent with other reviews. Qualitatively, the presence of ATI was associated with lower levels of infliximab and lower risk of disease control or remission. The presence of ATI also increased the risk of infusion reactions. When ascertained, the time to development of ATI varied from as little as 16 weeks to over a year. The time to ATA positivity varied (e.g., 50% of patients with detectable ATA at 28 weeks to a median time of 1 year). Finally, for both infliximab and adalimumab, immunosuppression was associated with less ADA positivity. Reviewers concluded that “…the lack of homogeneity in study design and methodologies used … limited the opportunity to establish the time-course and clinical consequences of anti-drug antibody development....” Although qualitative, reviewers included many studies and provided a detailed review of each not reported by the other meta-analyses.

Table 1. Estimated Prevalence of ADA From Meta-Analyses

Author

Included Studies

Drugs

Disease

Prevalence of ADA

IFX

ADL

Other a

IBD

RA

SpA

Pooled

(95% CI)

Range in Studies

Lee et al. (2012) (11)

Episodic

Maintenance

18b

20.8%

(19.2 to 22.5)

5

45.8%

(41.7 to 50.0)

10

12.4%

(10.8 to 14.1)

Nanda et al. (2013) (12)

11

22.4%-46%

Thomas et al. (2015) (13)

39c

25.3%

(19.5 to 32.3

15c

6.9%

(3.4 to 13.5)

20

15.8%

(9.6 to 24.7)

44

2.1%

(8.1 to 17.6)

11

8.9%

(3.8 to 19.2)

Meroni et al. (2015) (8)

14

19%-47%

14

15%-61%

5

d

26%-50%

12

5%-54%

3

9%-46%

3

d

18%-45%

ADA: antidrug antibodies; ADL: adalimumab; CI: confidence interval; IBD: inflammatory bowel disease; IFX: infliximab; RA: rheumatoid arthritis; SpA: spondyloarthropathy.

a Includes etanercept, golimumab, certolizumab.

b Includes 3 studies including both maintenance and episodic therapy.

c Number of comparisons in table; did not report studies for pooled prevalence.

d Also psoriasis.

Table 2. Results From Meta-Analyses of ADA and Clinical Response

Author

Included Studies

Drugs

Disease

Clinical Response: ADA vs None

IFX

ADL

Other a

IBD

RA

SpA

RR (95% CI)

OR (95% CI)

I2

Lee (2012) (11)

18

0.90

(0.79 to 1.02)

37%

Nanda (2013) (12)

11

0.33

(0.20 to 0.40)

70%

Garces (2013) (10)

12

b

0.32

(0.22 to 0.48)

46%

Thomas (2015) (13)

4

1.16

(0.66 to 2.03)

NR

13

0.27

(0.20 to 0.36)

NR

4

0.18

(0.09 to 0.37)

NR

9

0.42

(0.30 to 0.58)

NR

ADA: antidrug antibodies; ADL: adalimumab; CI: confidence interval; IBD: inflammatory bowel disease; IFX: infliximab; NR: not reported; OR: odds ratio; RA: rheumatoid arthritis; RR: relative risk; SpA: spondyloarthropathy.

a Includes etanercept, golimumab, certolizumab.

b Also psoriasis.

Table 3. Increased Risk of Adverse Reactions Associated With the Presence of ADA

Author

Included Studies

Drugs

Disease

Adverse Reactions: ADA vs None

IFX

ADL

Othersa

IBD

RA

SpA

OR (95% CI)

RR (95% CI)

Lee (2012) (11)

18

2.07

(1.61 to 2.67) a

Thomas (2015) (13)

NR

3.25

(2.335 to 4.51)

ADA: antidrug antibodies; ADL: adalimumab; CI: confidence interval; IBD: inflammatory bowel disease; IFX: infliximab; NR: not reported; OR: odds ratio; RA: rheumatoid arthritis; RR: relative risk; SpA: spondyloarthropathy.

a Infusion reaction.

A systematic review and meta-analysis by Pecoraro et al. (2017) selected 34 studies (total N=4273 patients), including RCTs (n=4), prospective observational (n=22), retrospective observational (n=6), and cross-sectional (n=2). (14) Studies evaluated RA (n=18), ulcerative colitis (n=2), CD (n=5), psoriatic arthritis (n=4), ankylosing spondylitis (n=5), plaque psoriasis (n=4), spondyloarthritis (n=1). Most of the patients (45%) received infliximab, 35% received adalimumab, and 21% received etanercept. None received golimumab or certolizumab. Reviewers identified studies published through August 2016 and rated study quality as good (n=17), fair (n=16), and poor (n=1). The effect of ADA was evaluated in 19 studies, showing a significant (p<0.05) reduction of response (RR=0.43; 95% CI, 0.3 to 0.63) in ADA-positive patients relative to ADA-negative patients, with adalimumab therapy demonstrating a greater reduction (RR=0.40; 95% CI, 0.25 to 0.65; p<0.001) than infliximab (RR=0.37; 95% CI, 0.2 to 0.7; p<0.001). Measures of heterogeneity were 84%, 57%, and 79%, respectively. Fourteen studies reported on the effect of ADA on clinical response (see Table 4). Eleven studies found the risk of developing ADA to be significantly (p=0.03) lower in patients treated with concomitant methotrexate therapy relative to treated those without methotrexate (RR=0.65; 95% CI, 0.47 to 0.9). Studies comparing treatment response with nonresponse (n=15) found responders to have a significantly (p<0.001) lower risk of developing ADA relative to nonresponders (RR=0.31; 95% CI, 0.18 to 0.52). The presence of ADA was associated with a significant reduction of anti-tumor necrosis factor α (TNF-α) serum concentration (see Table 5). Of the 20 studies (n>2800 patients) reporting data on adverse events, 31% (n=2 studies) developed infections, 18% (n=12 studies) developed injection-site reactions, 8% (n=11 studies) discontinued treatment due to adverse events, and 5% (n=1 study) developed serious adverse events (5%). Although ADA significantly reduced TNF-α response, the results should be viewed cautiously due to reported study limitations, including small numbers of studies included and considerable heterogeneity.

Table 4. Effect of Antidrug Antibodies on Clinical Response

Outcome Measures

No. Studies

MD

95% Confidence Interval

I2, %

p

Disease Activity Score 28

9

0.93

0.41 to 1.44

84

<0.001

BASDAI

2

-0.62

-1.51 to 0.27

0

0.17

ASDAS

2

0.96

-0.27 to 2.2

0

0.13

Psoriasis Area Severity Index

1

4.7

-1.15 to 9.25

NR

0.04

Adapted from Pecoraro et al (2017). (14)

ASDAS: Ankylosing Spondylitis Disease Activity Score; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; I2: heterogeneity measure; MD: mean difference; NR: not reported.

Table 5. Evaluation of Anti-TNF-α Concentration

Outcome Measures

No. Studies

MD, mg/L

95% Confidence Interval

I2, %

p

ADA-positive vs ADA-negative

8

-7.07

-8.9 to -5.25

98

<0.001

Responders vs no responders

13

2.77

1.97 to 3.58

82

<0.001

Adalimumab therapy

6

5.07

3.77 to 6.36

62

<0.001

Infliximab

4

2.74

0.59 to 4.89

62

<0.001

Etanercept

3

0.85

0.41 to 1.13

82

<0.001

DAS28 change from baseline

8

-2.18

-2.91 to -1.44

97

<0.001

Adapted from Pecoraro et al (2017). (14)

ADA: antidrug antibodies; DAS28: Disease Activity Score in 28 joints; I2: heterogeneity measure; MD: mean difference; TNF: tumor necrosis factor.

Cohort Studies

Three recent publications were identified, which were not included in a systematic review. (15-17) The results of the 3 publications were consistent with conclusions of the systematic reviews.

Arstikyte et al. (2015) prospectively evaluated the association between ADA and adverse events, clinical response, and serum drug levels in 143 symptomatic patients (62 with RA, 81 with SpA; mean age, 45 years) treated with TNF blockers in Lithuania. (15) All patients receiving adalimumab or infliximab were tested, and 1 in 3 patients was given etanercept (because it is more commonly used). A response in RA patients was defined as either good, moderate, or low using European League Against Rheumatism (EULAR) criteria (18); SpA disease activity was considered inactive, moderate, high, or very high by established criteria, (19) with inactive and moderately active disease defined as response. At least 3 months after therapy initiation, a single serum sample was obtained prior to dosing between 2012 and 2013; disease activity and other patient characteristics (e.g., symptom duration, health status) were assessed concurrently. Serum adalimumab, infliximab, and etanercept levels were obtained; ADA was assayed using a bridging ELISA. Of 57 patients receiving infliximab, 14 (24.6%) had detectable antibodies, with 13 of the 14 undetectable infliximab trough levels. Disease activity at baseline was unassociated with the development of ADA in either disease. In patients achieving response, infliximab and adalimumab trough levels were higher, but not significantly (p=0.09 and p=0.14, respectively). However, adalimumab concentrations were significantly higher in nonresponders (p<0.001). ATI were associated with infusion reactions but with little certainty (OR=5.9; 95% CI, 1.0 to 33.3) as was stopping infliximab treatment or changing agent. Study strengths included its prospective design, standardized assessments, and responder definition. Limitations involved the small number of nonresponders and no indication whether any eligible participants declined enrollment.

Frederiksen et al. (2014) conducted a single-center retrospective cohort study of IBD patients treated with infliximab (n=187) or adalimumab (n=57) in Denmark. (16) ADA were assayed using fluid-phase RIA; 49% of infliximab-treated patients developed antibodies compared with 21% of those treated with adalimumab. Development of ATA was associated with secondary nonresponse: the positive predictive value was 91% (95% CI, 59% to 100%), sensitivity was 50% (95% CI, 27% to 73%); the negative predictive value was 74% (95% CI, 57% to 87%), and specificity was 97% (95% CI, 82% to 100%) (values varied by adalimumab trough levels). The authors also reported that patients switching from infliximab to adalimumab who had antibodies were more likely to develop ATA. These findings are consistent with other studies and evaluation of ADA using RIA (a strength of this study). Conclusions were limited by the retrospective design and sample size.

Jani et al. (2015) measured ADA RIA together with drug levels in 331 RA patients treated with adalimumab (n=160) or etanercept (n=171) between 2008 and 2013. (17) Patients were participants in the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate, conducted in 60 centers across the United Kingdom. Disease activity was assessed using the Disease Activity Score in 28 joints (DAS28). Response was evaluated using EULAR response criteria or change in DAS28 score. Following 12 months of adalimumab therapy, ADA were detectable in 24.8% of patients (almost all were detectable by 6 months) and were associated with lower drug levels. Both routine (nontrough) drug levels and ATA were associated with DAS28 at 12 months. In predicting EULAR nonresponse, the area under the curve for an adalimumab concentration less than 5 mg/mL at 3 months was 0.66 (95% CI, 0.55 to 0.77) and 0.68 (95% CI, 0.54 to 0.81) for presence of ADA. None of the etanercept patients developed detectable ADA. Although derived from a well-established observational study designed to examine predictors (genetic and other) of treatment response, ADA levels were not used to inform treatment decisions. Study results corroborated other research findings.

While many studies have evaluated clinical validity using single ADA measurements, at least one assessed their persistence over time. Vande Casteele et al. (2013) analyzed infliximab trough and ATI levels using an HMSA with banked serum obtained from 90 IBD patients treated between 1999 and 2011. (20) ATI levels had been previously assayed using an ELISA-based test. A total of 1232 samples were evaluated (mean, 14 per patient). Treatment decisions were made solely on clinical evaluation and C-reactive protein levels. ATI were detected in 53 (59%) of 90 patients but subsequently were nondetectable in 15 (28%) of the 53. Persistent ATIs were associated with discontinuation of infliximab (RR=5.1; 95% CI, 1.4 to 19.0), but the wide confidence interval reflects considerable uncertainty. Although the transience of ATI in IBD has not been carefully scrutinized, if replicated, these results would suggest interpreting a single ATI result cautiously.

Cludts et al. (2017) conducted a single-center retrospective cohort analysis of patients with RA (n=18), psoriatic arthritis (n=9), or ankylosing spondylitis (n=12) in Italy. (21) Serum samples were taken prior to adalimumab therapy and after 12 and 24 weeks of treatment. Psoriatic arthritis and ankylosing spondylitis patients were grouped together (SpA) due to axial involvement in all psoriatic arthritis patients. Although adalimumab levels varied among patients (0 to 30 µg/mL), median levels were significantly lower at 12 and 24 weeks in ATA-positive samples, and antibody formation was associated with decreasing levels of circulating adalimumab. A reporter gene assay detected neutralizing antibodies against TNF antagonists in ATA-positive, therapeutic-negative patients; however, neutralization could not be confirmed in all ATA- positive samples due to adalimumab interference. There was a negative correlation between ATA levels and adalimumab in all groups, with 43.6% and 41% of the adalimumab-treated patients developing antibodies at 12 and 24 weeks, respectively. These percentages increased to 48.7% and 46% after subjecting the samples to acid treatment. There was a negative correlation between adalimumab trough levels and DAS28 and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) scores (p<0.001). There were no significant differences between BASDAI in ATA-positive compared with ATA-negative patients at 12 or 24 weeks. The study is consistent with others suggesting that adalimumab levels can serve as an indicator of ATA; however, limitations included small sample size, retrospective research design, and failure to confirm neutralization in all ATA-positive samples.

Using an observational, cross-sectional study design, Ara-Martin et al. (2017) analyzed the impact of immunogenicity on response to anti-TNF therapy in 137 adults with moderate-to-severe plaque psoriasis at 35 centers in Spain between 2012 and 2014. (22) All patients experienced secondary nonresponse to adalimumab (n=65), etanercept (n=47), and infliximab (n=19) after 6 or more months of treatment. Serum ADA was identified in 48%, 0%, and 42% of patients of patients treated with adalimumab, etanercept, and infliximab, respectively. Loss of efficacy was assessed using the Psoriasis Area and Severity Index (PASI; >5), 75% improvement in PASI score from baseline (PASI75), and/or the Physician Global Assessment (PGA, >2). PGA values for ADA-positive vs ADA-negative patients were significantly worse in the adalimumab group (3.7 vs 3.2; p=0.02) but not in the infliximab group. There was a significant negative linear correlation between serum drug concentrations and ADA in both the adalimumab group (p=0.001) and among the 3 groups combined (p=0.001), and a significant (p=0.019) correlation between serum ADA titer and body surface area. Unlike the other studies, in this study, the use of concomitant antirheumatic drugs was not associated with anti-TNF immunogenicity in any of the groups. This study provided evidence of antibody development against adalimumab and infliximab (not against etanercept) in patients with psoriasis, with ADA formation accounting for half of the secondary nonresponse associated with these therapies. However, conclusions were limited due to the cross-sectional study design, use of ELISA to detect ADAs due to drug interference, the potential presence of neutralizing antibodies as confounding factors, and limited information about patients’ health status prior to the study period.

A case-control, longitudinal study by Lombardi et al. (2016) excludes possible confounding factors by analyzing adalimumab treatment for psoriasis in 5 distinct groups, including individuals who received: biologic therapies after switching from adalimumab (n=20); ongoing adalimumab therapy (n=30); novel adalimumab therapy (n=30); biologic therapies other than adalimumab (n=15); and no treatment with immunosuppressants or biologics (n=15), serving as a quasi-control. (23) The clinical severity of psoriasis was scored using the PASI. At 12-month follow-up, ADA was highest (87%) in patients who received biologic therapies after switching from adalimumab. The false-positive rate was 23% for adalimumab detection and 22% for anti-adalimumab antibodies in individuals who were never treated with adalimumab. There was no significant difference in median PASI score between the anti-adalimumab antibody-negative patients (1.1) and the anti-adalimumab antibody-positive patients (4.0). There was no association between PASI score or TNF-α concentration and the presence of anti-adalimumab antibodies in patients receiving adalimumab. Additionally, there were no significant differences in TNF-α and C-reactive protein concentrations. Study limitations included its observational design, small sample size, use of ELISA to measure ADA, and high variability of results. The authors concluded that the assay has limited clinical utility.

Section Summary: Clinical Validity

A large body of evidence has evaluated the clinical validity of ADA testing. ADA have been associated with secondary nonresponse in RA, SpA, and possibly IBD. The presence of ADA has been consistently associated with an increased risk of infusion-site reaction related to infliximab and injection-site reactions related to adalimumab. A concomitantly administered immunosuppressant agent may reduce the risk of developing ADA. Although ADA significantly reduced TNF-α response in a recent meta-analysis, considerable heterogeneity limits those findings. In addition, a recent observational study found no association between concomitant immunosuppressants and anti-TNF immunogenicity in patients with psoriasis; and a second cohort study found no association between PASI score or TNF-α concentration and the presence of anti-adalimumab antibodies in patients receiving adalimumab to treat psoriasis.

Clinical Utility

Several algorithms have been developed to manage patients with IBD (24-26) and RA (27) who have relapsed during TNF-inhibitor therapy. These algorithms are generally based on evidence that has indicated an association between ADA, reduced serum drug levels, and relapse. None of the algorithms has included evidence demonstrating improved health outcomes, such as reduced time to recovery from relapse (response).

Afif et al. (2010) evaluated the clinical utility of measuring ATI (referred to as human antichimeric antibodies in the study) and infliximab concentrations by retrospectively reviewing patient medical records. (28) Record review from 2003 to 2008 identified 155 patients who had had ATI, had data on infliximab concentrations and met the study inclusion criteria. A single physician ordered 72% of the initial tests. The authors retrospectively determined clinical response to infliximab. Forty-seven percent of patients were on concurrent immunosuppressive medication. The main indications for testing were loss of response to infliximab (49%), partial response after initiation of infliximab (22%), and possible autoimmune or delayed hypersensitivity reaction (10%). ATI were identified in 35 (23%) patients and therapeutic infliximab concentrations in 51 (33%) patients. Of 177 tests assessed, the results impacted treatment decisions in 73%. In ATI-positive patients, change to another anti-TNF agent was associated with a complete or partial response in 92% of patients, whereas dose escalation occurred in 17%.

The authors concluded that measurement of ATI and infliximab concentration had a clinically useful effect on patient management. The strategy of increasing infliximab dose in patients with ATI was ineffective whereas in patients with subtherapeutic infliximab concentrations this strategy was a good alternative to changing to another anti-TNF agent. (28) Study limitations included the retrospective design and use of ELISA testing for ATI. Because there was no control group, one cannot determine what changes in management would have been made absent ATI measurement. Because clinicians are likely to change management for patients who do not achieve or maintain a clinical response, it is important to understand how these management decisions differ when ATI are measured.

In 2014, Steenholdt et al. reported results of a noninferiority trial and cost-effectiveness analysis of 69 patients with CD who relapsed (CDAI ≥220 and/or ≥1 draining perianal fistula) during infliximab therapy. (6) Patients were randomized to infliximab dose intensification (5 mg/kg every 4 weeks) or algorithmic treatment based on serum infliximab level and ATI: Patients with subtherapeutic infliximab level (<0.5 μg/mL) (29) had infliximab dose increased if ATI were undetectable or were switched to adalimumab if ATI were detectable; patients with therapeutic infliximab level underwent repeat testing of infliximab and ATI levels if ATI were detectable or diagnostic reassessment if ATI were undetectable. Serum infliximab and ATI levels were measured in all patients using RIA in single-blind fashion (patients were unaware, but investigators were aware of test results). Randomized groups were similar at baseline; overall, 55 (80%) of 69 patients had nonfistulizing disease. Most patients (70%) had therapeutic serum infliximab levels without detectable ATI; revised diagnoses in 6 (24%) of 25 such patients in the algorithm arm (30) included bile acid malabsorption, strictures, and irritable bowel syndrome. In both intention-to-treat and per-protocol analyses, similar proportions of patients in each randomized group achieved clinical response at week 12, defined as a minimum 70-point reduction from baseline CDAI for patients with nonfistulizing disease and a minimum 50% reduction in active fistulas for patients with fistulizing disease (intention-to- treat, 58% in the algorithm group vs 53% in the control group; p=0.810; per-protocol; 47% in the algorithm group vs 53% in the control group; p=0.781). Only the intention-to-treat analysis fell within the prespecified noninferiority margin of -25% for the difference between groups.

Conclusions on the noninferiority of an algorithmic approach compared with dose intensification from this trial are limited. The noninferiority margin was arguably large and was exceeded in the conservative per-protocol analysis. Dropouts were frequent and differential between groups; 17 (51%) of 33 patients in the algorithm group and 28 (78%) of 36 patients in the control group completed the 12-week trial. A large proportion of patients (24%) in the algorithmic arm were potentially misdiagnosed (i.e., CD flare was subsequently determined not to be the cause of relapse); the comparable proportion in the control arm was not reported. In most patients (80% who had nonfistulizing disease), only a subjective measure of treatment response was used (minimum 70-point reduction from baseline CDAI).

Roblin et al. (2014) conducted a single-center, prospective observational study of 82 patients with IBD (n=45 CD, n=27 ulcerative colitis) with clinical relapse (CDAI >220 or Mayo Clinic >5) during treatment with adalimumab 40 mg every 2 weeks. (31) For all patients, trough adalimumab levels and ADA were measured in a blinded fashion using ELISA, and adalimumab dose was optimized to 40 mg weekly. Those who did not achieve clinical remission (CDAI <150 or Mayo score <2) within 4 months underwent repeat trough adalimumab and anti-adalimumab antibody testing and were switched to infliximab. Clinical and endoscopic responses after adalimumab optimization and after infliximab therapy for 6 months were compared across 3 groups: 1) those with a therapeutic adalimumab level (>4.9 μg/mL32), 2) those with a subtherapeutic adalimumab level and undetectable ATA; and 3) those with a subtherapeutic adalimumab level and detectable ATA. After adalimumab optimization, more group 2 patients achieved clinical remission (16 [67%] of 24 patients) than group 1 (12 [29%] of 41 patients; p<0.01 vs group 2) and group 3 (2 [12%] of 17 patients; p<0.01 vs group 2) patients. Duration of remission was longest in group 2 (mean, 15 months) compared with group 1 (mean, 5 months) and group 3 (mean, 4 months; p<0.01 for both comparisons vs group 2). At 1 year, 13 (52%) of 24 patients in group 2 maintained clinical remission compared with no patients in groups 1 or 3 (p<0.01 for both comparisons vs group 2). Results were similar when remission was defined using calprotectin levels (<250 μg/g stool) or endoscopic Mayo score (<2).

Fifty-two patients (n=30 CD, n=22 ulcerative colitis) who failed to achieve clinical remission after adalimumab optimization were switched to infliximab. More patients in group 3 achieved clinical remission (12 [80%] of 15 patients) than in group 1 (2 [7%] of 29 patients) or group 2 (2 [25%] of 8 patients; p<0.01 for both comparisons vs group 3). Duration of response after switching to infliximab was longest in group 3 (mean, 14 months) compared with group 1 (mean, 3 months) and group 2 (mean, 5 months; p<0.01 for both comparison vs group 3). At 1 year, 8 (55%) of 15 patients in group 3 maintained clinical remission compared with no patients in groups 1 or 2 (p<0.01 for both comparisons vs group 3). Results were similar using objective measures of clinical remission (calprotectin level, endoscopic Mayo score).

These results suggested that patients with IBD who relapse on adalimumab and have subtherapeutic serum adalimumab levels may benefit from a higher adalimumab dose if ATA are undetectable or from a change to another TNF inhibitor if ATA are detectable. Relapsed patients who have therapeutic serum adalimumab levels may benefit from change to a different drug class. Strengths of the study include its use of subjective and objective measures of remission and blinded serum drug level and ATA monitoring. However, results were influenced by the small sample size, use of ELISA for antibody testing, and lack of ADA levels for decision making. Subsequent study comparing the management using the algorithm proposed with usual care is needed. Ideally, using more than 1 method of assaying antibodies would further assessment of analytic validity. Finally, the lead author of the study received lecture fees from the ADA test provider (Theradiag).

Section Summary: Clinical Utility

Convincing evidence for the clinical utility of ADA testing currently is lacking. Uncontrolled retrospective studies in IBD have demonstrated the impact of ADA testing on treatment decisions but cannot demonstrate improved patient outcomes compared with a no-testing strategy. Additional limitations of these studies include lack of clinical follow-up after treatment decisions were made (in Afif et al. [28]) and lack of clinical assessments to guide treatment decisions (in Steenholdt et al. [29]). Additionally, determination of a clinically relevant threshold for ADA level is complicated by the use of various assay methods. A small, nonrandomized prospective study suggested that ADA levels may be informative in relapsed patients with IBD who have low serum adalimumab levels, but this finding requires confirmation in larger, randomized trials. Methodologic flaws, including relapse misclassification, limit conclusions from the RCT in patients with relapsed IBD. Direct or indirect evidence for clinical utility in patients with RA or SpA was not identified. Finally, although ADA are associated with increased risk of infliximab infusion- and adalimumab injection-site reactions, whether testing for ADA can reduce that risk is unclear. For example, the 2013 Lichtenstein systematic review of infliximab-related infusion reactions concluded: “…there is a paucity of systematic and controlled data on the risk, prevention, and management of infusion reactions to infliximab.” (26) He added that “[m]ore randomised controlled trials are needed in order to investigate the efficacy of the proposed preventive and management algorithms.”

Summary of Evidence

For individuals who have rheumatoid arthritis, psoriatic arthritis, or juvenile idiopathic arthritis; inflammatory bowel disease (e.g., Crohn disease, ulcerative colitis); ankylosing spondylitis; or plaque psoriasis who receive evaluation for anti-TNF-α inhibitor ATI or to adalimumab, the evidence includes multiple systematic reviews, a randomized controlled trial, and observational studies. Relevant outcomes are test accuracy and validity, change in disease status, health status measures, quality of life, and treatment-related morbidity. ATI or antibodies to adalimumab develop in a substantial proportion of treated patients and are believed to neutralize or enhance clearance of the drugs. Considerable evidence has demonstrated an association between ADA and secondary nonresponse as well as injection-site and infusion-site reactions. The clinical usefulness of measuring ADA hinges on whether test results inform management changes, thereby leading to improved outcomes, compared with management directed by symptoms, clinical assessment, and standard laboratory evaluation. Limited evidence has described management changes after measuring ADA. A small randomized controlled trial in patients with Crohn disease comparing ATI-informed management of relapse with standard dose escalation did not demonstrate improved outcomes with the ATI-informed approach. Additionally, many assays—some having significant limitations—have been used in studies; ADA threshold values that are informative for discriminating treatment responses have not been established. The evidence is insufficient to determine the effects of the technology on health outcomes.

Practice Guidelines and Position Statements

American College of Gastroenterology et al.

Clinical guidelines from the American College of Gastroenterology, (33, 34) the American College of Rheumatology, (35) and the European League Against Rheumatism (36) have not included recommendations for testing for antidrug antibodies in patients treated with tumor necrosis factor (TNF) inhibitors. An important question included in the European League research recommendations was whether “measurement of serum drug and/or drug antibody levels [is] useful in clinical practice?”

National Institute for Health and Care Excellence

In 2016, the National Institute for Health and Care Excellence issued guidance on therapeutic monitoring of TNF-α inhibitors in the treatment of patients with Crohn disease. (37) The Institute recommended that laboratories monitoring TNF-α inhibitors in patients with Crohn disease who have lost response to the treatment, should work with clinicians to collect data through either a prospective study, a local audit, or a registry.

Ongoing and Unpublished Clinical Trials

Some currently unpublished trials that might influence this review are listed in Table 6.

Table 6. Summary of Key Trials

NCT No.

Trial Name

Planned Enrollment

Completion Date

Ongoing

NCT01638715

A Randomized, Multi-Center Biomarker Trial to Predict Therapeutic Responses of Patients With Rheumatoid Arthritis to a Specific Biologic Mode of Action

200

Dec 2017

Unpublished

NCT01895764

Effect of the Combination of Methotrexate and Adalimumab on Reduction of Immunization in Ankylosing Spondylitis (COMARIS)

110

Apr 2015 (completed)

NCT01971918

Comparative Analysis of Two Therapeutic Strategies in Patients With Spondyloarthritis Treated With Anti-TNF Biologics (STRADA)

104

Nov 2016 (terminated)

NCT: national clinical trial.

Contract:

Each benefit plan, summary plan description or contract defines which services are covered, which services are excluded, and which services are subject to dollar caps or other limitations, conditions or exclusions. Members and their providers have the responsibility for consulting the member's benefit plan, summary plan description or contract to determine if there are any exclusions or other benefit limitations applicable to this service or supply. If there is a discrepancy between a Medical Policy and a member's benefit plan, summary plan description or contract, the benefit plan, summary plan description or contract will govern.

Coding:

According to materials from Prometheus Laboratories on Anser™IFX and Anser™ADA, these tests will be reported using 1 unit of CPT code 84999. There are no specific codes for these tests.

CODING:

Disclaimer for coding information on Medical Policies

Procedure and diagnosis codes on Medical Policy documents are included only as a general reference tool for each policy. They may not be all-inclusive.

The presence or absence of procedure, service, supply, device or diagnosis codes in a Medical Policy document has no relevance for determination of benefit coverage for members or reimbursement for providers. Only the written coverage position in a medical policy should be used for such determinations.

Benefit coverage determinations based on written Medical Policy coverage positions must include review of the member’s benefit contract or Summary Plan Description (SPD) for defined coverage vs. non-coverage, benefit exclusions, and benefit limitations such as dollar or duration caps.

CPT/HCPCS/ICD-9/ICD-10 Codes

The following codes may be applicable to this Medical policy and may not be all inclusive.

CPT Codes

84999

HCPCS Codes

None

ICD-9 Diagnosis Codes

Refer to the ICD-9-CM manual

ICD-9 Procedure Codes

Refer to the ICD-9-CM manual

ICD-10 Diagnosis Codes

Refer to the ICD-10-CM manual

ICD-10 Procedure Codes

Refer to the ICD-10-CM manual


Medicare Coverage:

The information contained in this section is for informational purposes only. HCSC makes no representation as to the accuracy of this information. It is not to be used for claims adjudication for HCSC Plans.

The Centers for Medicare and Medicaid Services (CMS) does not have a national Medicare coverage position. Coverage may be subject to local carrier discretion.

A national coverage position for Medicare may have been developed since this medical policy document was written. See Medicare's National Coverage at <http://www.cms.hhs.gov>.

References:

1. Bendtzen K. Personalized medicine: theranostics (therapeutics diagnostics) essential for rational use of tumor necrosis factor-alpha antagonists. Discov Med. Apr 2013; 15(83):201-211. PMID 23636137

2. Kopylov U, Mazor Y, Yavzori M, et al. Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies. Inflamm Bowel Dis. Sep 2012; 18(9):1628-1633. PMID 22038899

3. Wang SL, Ohrmund L, Hauenstein S, et al. Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum. J Immunol Methods. Aug 31 2012; 382(1-2):177-188. PMID 22691619

4. Hernandez-Breijo B, Chaparro M, Cano-Martinez D, et al. Standardization of the homogeneous mobility shift assay protocol for evaluation of anti-infliximab antibodies. Application of the method to Crohn's disease patients treated with infliximab. Biochem Pharmacol. Dec 15 2016; 122:33-41. PMID 27664854

5. Steenholdt C, Bendtzen K, Brynskov J, et al. Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn's disease: post hoc analysis of a randomized controlled trial. Am J Gastroenterol. Jul 2014; 109(7):1055-1064. PMID 24796769

6. Steenholdt C, Brynskov J, Thomsen OO, et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut. Jun 2014; 63(6):919-927. PMID 23878167

7. Wang SL, Hauenstein S, Ohrmund L, et al. Monitoring of adalimumab and antibodies-to-adalimumab levels in patient serum by the homogeneous mobility shift assay. J Pharm Biomed Anal. May 5 2013; 78-79:39-44. PMID 23454676

8. Meroni PL, Valentini G, Ayala F, et al. New strategies to address the pharmacodynamics and pharmacokinetics of tumor necrosis factor (TNF) inhibitors: A systematic analysis. Autoimmun Rev. Sep 2015; 14(9):812-829. PMID 25985765

9. White CM, Ip S, McPheeters M, et al. Using Existing Systematic Reviews To Replace De Novo Processes in Conducting Comparative Effectiveness Reviews Methods Guide for Effectiveness and Comparative Effectiveness Reviews. Rockville MD; 2008.

10. Garces S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis. Dec 2013; 72(12):1947-1955. PMID 23223420

11. Lee LY, Sanderson JD, Irving PM. Anti-infliximab antibodies in inflammatory bowel disease: prevalence, infusion reactions, immunosuppression and response, a meta-analysis. Eur J Gastroenterol Hepatol. May 27 2012; 24(9):1078-1085. PMID 22647738

12. Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol. Jan 2013; 108(1):40-47; quiz 48. PMID 23147525

13. Thomas SS, Borazan N, Barroso N, et al. Comparative Immunogenicity of TNF Inhibitors: Impact on Clinical Efficacy and Tolerability in the Management of Autoimmune Diseases. A Systematic Review and Meta-Analysis. BioDrugs. Aug 2015; 29(4):241-258. PMID 26280210

14. Pecoraro V, De Santis E, Melegari A, et al. The impact of immunogenicity of TNFalpha inhibitors in autoimmune inflammatory disease. A systematic review and meta-analysis. Autoimmun Rev. Jun 2017; 16(6):564-575. PMID 28411169

15. Arstikyte I, Kapleryte G, Butrimiene I, et al. Influence of Immunogenicity on the Efficacy of Long-Term Treatment with TNF alpha Blockers in Rheumatoid Arthritis and Spondyloarthritis Patients. Biomed Res Int. 2015; 2015:604872. PMID 26064930

16. Frederiksen MT, Ainsworth MA, Brynskov J, et al. Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBD. Inflamm Bowel Dis. Oct 2014; 20(10):1714-1721. PMID 25069030

17. Jani M, Chinoy H, Warren RB, et al. Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis. Arthritis Rheumatol. May 2015; 67(8):2011-2019. PMID 26109489

18. van Gestel AM, Prevoo ML, van 't Hof MA, et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum. Jan 1996; 39(1):34-40. PMID 8546736

19. Castillo-Gallego C, Aydin SZ, Marzo-Ortega H. Clinical utility of the new ASAS criteria for spondyloarthritis and the disease activity score. Curr Rheumatol Rep. Oct 2011; 13(5):395-401. PMID 21748416

20. Vande Casteele N, Gils A, Singh S, et al. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol. Jun 2013; 108(6):962-971. PMID 23419382

21. Cludts I, Spinelli FR, Morello F, et al. Anti-therapeutic antibodies and their clinical impact in patients treated with the TNF antagonist adalimumab. Cytokine. Aug 2017; 96:16-23. PMID 28279855

22. Ara-Martin M, Pinto PH, Pascual-Salcedo D. Impact of immunogenicity on response to anti-TNF therapy in moderate-to-severe plaque psoriasis: results of the PREDIR study. J Dermatolog Treat. Nov 2017; 28(7):606-612. PMID 28274164

23. Lombardi G, Perego S, Sansoni V, et al. Anti-adalimumab antibodies in psoriasis: lack of clinical utility and laboratory evidence. BMJ Open. Dec 09 2016; 6(12):e011941. PMID 27940624

24. Eser A, Primas C, Reinisch W. Drug monitoring of biologics in inflammatory bowel disease. Curr Opin Gastroenterol. Jul 2013; 29(4):391-396. PMID 23703367

25. Khanna R, Sattin BD, Afif W, et al. Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease. Aliment Pharmacol Ther. Sep 2013; 38(5):447-459. PMID 23848220

26. Lichtenstein GR. Comprehensive review: antitumor necrosis factor agents in inflammatory bowel disease and factors implicated in treatment response. Therap Adv Gastroenterol. Jul 2013; 6(4):269-293. PMID 23814608

27. Garces S, Antunes M, Benito-Garcia E, et al. A preliminary algorithm introducing immunogenicity assessment in the management of patients with RA receiving tumour necrosis factor inhibitor therapies. Ann Rheum Dis. Jun 2014; 73(6):1138-1143. PMID 23666932

28. Afif W, Loftus EV, Jr., Faubion WA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol. May 2010; 105(5):1133-1139. PMID 20145610

29. Steenholdt C, Bendtzen K, Brynskov J, et al. Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease. Scand J Gastroenterol. Mar 2011; 46(3):310-318. PMID 21087119

30. Tan M. Importance of defining loss of response before therapeutic drug monitoring. Gut. Jul 16 2014. PMID 25031226

31. Roblin X, Rinaudo M, Del Tedesco E, et al. Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases. Am J Gastroenterol. Aug 2014; 109(8):1250-1256. PMID 24913041

32. Roblin X, Marotte H, Rinaudo M, et al. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. Jan 2014; 12(1):80-84 e82. PMID 23891927

33. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. Mar 2010; 105(3):501-523; quiz 524. PMID 20068560

34. Lichtenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn's disease in adults. Am J Gastroenterol. Feb 2009; 104(2):465-483; quiz 464, 484. PMID 19174807

35. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). May 2012; 64(5):625-639. PMID 22473917

36. Smolen JS, Landewe R, Breedveld FC, et al. European League Against Rheumatism (EULAR) recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. Mar 2014; 73(3):492-509. PMID 24161836

37. National Institute for Health and Care Excellence (NICE). Therapeutic monitoring of TNF-alpha inhibitors in Crohn’s disease (LISA-TRACKER ELISA kits, IDKmonitor ELISA kits, and Promonitor ELISA kits) [DG22]. 2016. Available at <https://www.nice.org.uk> (accessed October 27, 2017).

38. Measurement of Serum Antibodies to Infliximab and Adalimumab. Chicago, Illinois: Blue Cross Blue Shield Association Medical Policy Reference Manual (November 2017) Medicine 2.04.84.

Policy History:

Date Reason
4/15/2018 Documented updated with literature review. Coverage unchanged. References 4, 14, 21-23 added.
4/15/2017 Reviewed. No changes.
4/1/2016 Document updated with literature review. Coverage unchanged.
5/1/2015 Reviewed. No changes.
3/1/2014 New medical document. Measurement of antibodies to infliximab in a patient receiving treatment with infliximab, either alone or as a combination test which includes the measurement of serum infliximab levels, is considered experimental, investigational and/or unproven. Measurement of antibodies to adalimumab in a patient receiving treatment with adalimumab, either alone or as a combination test which includes the measurement of serum adalimumab levels, is considered experimental, investigational and/or unproven.

Archived Document(s):

Back to Top